REFERENCES
1. Ahn MS, Jackler RK, Lustig LR. The early history of the neurofibromatoses: evolution of the concept of neurofibromatosis type 2. Arch Otolaryngol Head Neck Surg. 1996;122:1240-9.
3. Huson SM, Hughes RAC. The neurofibromatoses: a pathogenetic and clinical overview. Chapman & Hall Medical; 1994. https://archive.org/details/neurofibromatose0000unse. [Last accessed on 7 Jan 2026].
4. Mossé A, Cavalié
5. Ruggieri M, Praticò AD, Serra A, et al. Early history of neurofibromatosis type 2 and related forms: earliest descriptions of acoustic neuromas, medical curiosities, misconceptions, landmarks and the pioneers behind the eponyms. Childs Nerv Syst. 2017;33:549-60.
6. Gardner WJ, Turner O. Bilateral acoustic neurofibromas: further clinical and pathologic data on hereditary deafness and Recklinghausen’s disease. Arch Neurol Psychiatry. ;1940, 44(1):76-99.
7. Gardner WJ, Frazier CH. Bilateral acoustic neurofibromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members. Arch Neurol Psychiatry. 1930;23:266-302.
8. Moyes PD. Familial bilateral acoustic neuroma affecting 14 members from four generations. J Neurosur. 1968;29:78-82.
9. Young DF, Eldridge R, Gardner WJ. Bilateral acoustic neuroma in a large kindred. JAMA. 1970;214:347-53.
10. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature. 1986;322:644-7.
11. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363:515-21.
12. Barker D, Wright E, Nguyen K, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science. 1987;236:1100-2.
13. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72:791-800.
14. Hiruta R, Saito K, Bakhit M, Fujii M. Current progress in genomics and targeted therapies for neurofibromatosis type 2. Fukushima J Med Sci. 2023;69:95-103.
15. Ghalavand MA, Asghari A, Farhadi M, Taghizadeh-Hesary F, Garshasbi M, Falah M. The genetic landscape and possible therapeutics of neurofibromatosis type 2. Cancer Cell Int. 2023;23:99.
16. Emanuel BS, Zackai EH, Medne L. Emanuel Syndrome. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1263/ [Last accessed on 11 Oct 2025].
17. Sperfeld AD, Hein C, Schröder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain. 2002;125:996-1004.
18. Hexter A, Jones A, Joe H, et al. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet. 2015;52:699-705.
19. Forde C, King AT, Rutherford SA, et al. Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol. 2021;23:1113-24.
20. Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81:496-9.
21. Feucht M, Griffiths B, Niemüller I, et al. Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders. Acta Ophthalmol. 2008;86:882-6.
22. Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics. 2005;36:21-34.
23. Pathmanaban ON, Sadler KV, Kamaly-Asl ID, et al. Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. JAMA Neurol. 2017;74:1123-9.
24. Halliday D, Emmanouil B, Evans DG. Updated protocol for genetic testing, screening and clinical management of individuals at-risk of NF2-related schwannomatosis. Clin Genet. 2023;103:540-52.
25. Halliday D, Parry A, Evans DG. Neurofibromatosis type 2 and related disorders. Curr Opin Oncol. 2019;31:562-7.
26. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26:93-7.
27. Evans DG, Ramsden RT, Shenton A, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet. 2007;44:424-8.
28. Plotkin SR, Messiaen L, Legius E, et al.; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med. 2022;24:1967-7.
29. Jiramongkolchai P, Schwartz MS, Friedman RA. Management of Neurofibromatosis Type 2-Associated Vestibular Schwannomas. Otolaryngol Clin North Am. 2023;56:533-41.
30. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74:1288-93.
31. Tosi U, Maayan O, An A, et al. Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis. J Neurooncol. 2022;156:431-41.
32. Puataweepong P, Dhanacha M, Ruangkanchanasetr R, et al. Long-term clinical outcomes of stereotactic radiotherapy for bilateral vestibular schwannomas in neurofibromatosis type 2 patients. J Neurooncol. 2023;164:587-95.
33. Bin-Alamer O, Faramand A, Alarifi NA, et al. Stereotactic radiosurgery for vestibular schwannoma in neurofibromatosis type 2: an international multicenter case series of response and malignant transformation risk. Neurosurgery. 2023;92:934-44.
34. Evans DG, Halliday D, Obholzer R, et al.; English Specialist NF2 Research Group. Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression. Neurooncol Adv. 2023;5:vdad025.
35. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004:3,391-400.
36. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358-67.
37. Plotkin SR, Allen J, Dhall G, et al. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023;25:1498-506.
38. Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner VF. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. 2015;272:3857-60.
39. Screnci M, Puechmaille M, Berton Q, Khalil T, Mom T, Coll G. Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation. J Clin Med. 2024;13:7488.
40. Renzi S, Michaeli O, Salvador H, et al. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer. 2020;67:e28228.
41. Webb MJ, Neth BJ, Webb LM, et al. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neuro Oncol Adv. 2023;5:vdad123.
42. Farschtschi S, Merker VL, Wolf D, et al. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016;133:475-80.
43. Shi J, Lu D, Gu R, et al. Integrated analysis of transcriptome and differential methylation of neurofibromatosis type 2 vestibular schwannomas. World Neurosurg. 2022;157:e66-e76.
44. Tsuchiya T, Miyawaki S, Teranishi Y, et al. Current molecular understanding of central nervous system schwannomas. Acta Neuropathol Commun. 2025;13:24.
45. Chang LS, Oblinger JL, Smith AE, et al.; Synodos for NF2 Consortium. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021;16:e0252048.
46. Plotkin SR, Yohay KH, Nghiemphu PL, et al.; INTUITT-NF2 Consortium. Brigatinib in NF2-related schwannomatosis with progressive tumors. N Engl J Med. 2024;390:2284-94.
47. Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2012;14:1163-70.
48. Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Neuro Oncol. 2010;31:1135-43.
49. Goutagny S, Raymond E, Esposito-Farese M, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol. 2015;122:313-20.
50. Karajannis MA, Legault G, Hagiwara M, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2014;16:292-7.
51. Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550-60.
52. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430-42.
53. Weiss BD, Wolters PL, Plotkin SR, et al. NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-RELATED PLEXIFORM NEUROFIBROmas. J Clin Oncol. 2021;39:797-806.
54. Moertel CL, Hirbe AC, Shuhaiber HH, et al.; ReNeu Trial Investigators. ReNeu: a pivotal, phase iib trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43:716-29.
56. Nagel A, Huegel J, Petrilli A, et al. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis. Oncogene. 2024;43:921-30.
57. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713-22.
58. Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023;24:11939.
60. Le Guiner C, Servais L, Montus M, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.
61. Abdul-Razak H, Malerba A, Dickson G. Advances in gene therapy for muscular dystrophies. F1000Res. 2016;5:2030.
62. Elangkovan N, Dickson G. Gene Therapy for Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021;8:S303-16.
63. Prabhakar S, Beauchamp RL, Cheah PS, et al. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022;26:169-80.
